Alzheimer's Disease Global Clinical Trials Review, H2, 2019

Alzheimer's Disease Global Clinical Trials Review, H2, 2019

Summary

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H2, 2019 provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's DiseaseReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2019*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2019*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
      • Table Figure 3: Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
    • Table Figure 9: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2019*
    • Table Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2019*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
    • Table Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
    • Table Figure 12: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2019*
    • Table Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2019*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
    • Table Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
    • Table Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by Phase
    • Table Figure 15: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2019*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2019*
    • In Progress Trials by Phase
      • Table Figure 16: Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Clinical Trials by Trial Status
    • Table Figure 17: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2019*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Clinical Trials by End Point Status
    • Table Figure 18: Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2019*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
    • Table Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Prominent Sponsors
    • Table Figure 21: Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
    • Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
      • Table Figure 22: Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
      • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Prominent Drugs
    • Table Figure 23: Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Latest Clinical Trials News on Alzheimer's Disease
    • Nov 26, 2019: New study by TauRx shows a minimum dose of Hydromethylthionine could slow cognitive decline and brain atrophy in mild-to-moderate Alzheimer's Disease
    • Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference
    • Nov 20, 2019: Cognition Therapeutics to give webcast presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019
    • Nov 20, 2019: New research demonstrates second direct link between inflammasome activation and Alzheimer's Disease
    • Nov 20, 2019: Tonix Pharmaceuticals completes pre-IND meeting with FDA for TNX-102 SL as a clinical candidate for alcohol use disorder
    • Nov 19, 2019: Oligomerix and Feinstein Institutes publish In Vivo Alzheimer's Disease treatment data
    • Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial ofAcute Psychosis in Patients with Schizophrenia
    • Nov 12, 2019: Avanir Pharmaceuticals to continue clinical development of investigational AVP-786 for the treatment of agitation in patients with Alzheimer's Dementia
    • Nov 12, 2019: MGC Pharma receives first Australian Government Grant for CogniCann phase IIb clinical trial, progress towards LSE dual listing
    • Nov 11, 2019: ORYZON to present data on vafidemstat at Upcoming International Conferences
    • Nov 08, 2019: EIP Pharma reports mixed results from neflamapimod Alzheimer's trial
    • Nov 07, 2019: EIP Pharma announces U.S. FDA grants Fast-Track Designation to Neflamapimod as a treatment for Dementia with Lewy Bodies (DLB)
    • Nov 07, 2019: Inflazome provides update on Inzomelid
    • Nov 07, 2019: Inflazome provides update on Somalix
    • Nov 06, 2019: Alzheon publication defines new path for 2nd generation anti-amyloid drugs for Alzheimer's Disease, supporting launch of phase 3 study with ALZ-801 oral tablet
    • Nov 04, 2019: Alzheimer's drug Oligomannate gets conditional approval in China
    • Nov 04, 2019: AZTherapies to present at the 25th Annual BIO-EUROPE International Partnering Conference
    • Nov 04, 2019: Biogen to host investor webcasts from clinical trials on Alzheimer's Disease (CTAD) Congress
    • Oct 30, 2019: Cyclo Therapeutics signs agreement with Worldwide Clinical Trials to conduct Alzheimer's Disease clinical trial
    • Oct 29, 2019: Unique Alzheimer's Disease Tau vaccine shows great potential in pre-clinical studies
    • Oct 24, 2019: Cassava Sciences clinical results in Alzheimer's selected as late-breaking news at CTAD 2019
    • Oct 23, 2019: Biogen plans to seek FDA approval for Alzheimer's drug
    • Oct 22, 2019: Oligomerix presents preclinical data on Lead Alzheimer's disease candidate at Neuroscience 2019
    • Oct 21, 2019: INmune Bio announces potentially strong link between obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting
    • Oct 17, 2019: ProMIS Neurosciences advances Alzheimers disease program targeting neurotoxic forms of tau
    • Oct 17, 2019: INmune Bio announces presentation of data related to its lead compound XPro1595 at the Society for Neuroscience's Annual Meeting
    • Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein DegradationSummit
    • Oct 10, 2019: BioXcel Therapeutics provides update on its Schizophrenia drug candidate BXCL501
    • Oct 09, 2019: IntelGenx receives positive DSMB recommendation for Montelukast VersaFilm phase 2a trial
    • Oct 08, 2019: ProMIS Neurosciences identifies novel antibody candidates for multiple system atrophy
    • Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat
    • Oct 03, 2019: ACADIA Pharmaceuticals announces late-breaking oral presentation of the phase 3
    • Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients
    • Sep 30, 2019: Sovateltide (PMZ-1620), an Endothelin-B receptor agonist, has the potential to be a first-inclass neuronal progenitor cell therapeutics
    • Sep 30, 2019: Cognitive Improvement Demonstrated With Xanamem: Actinogen Medical
    • Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study
    • Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
    • Sep 24, 2019: Gene therapy shows promise repairing brain tissue damaged by stroke
    • Sep 23, 2019: ORYZON presents new data on vafidemstat
    • Sep 20, 2019: AC Immune receives first milestone payment from Lilly in small molecule Tau Morphomer program
    • Sep 19, 2019: Tetra Therapeutics sees rapid patient recruitment and representative patient diversity in its PICASSO Phase 2 Alzheimer's Disease Trial
    • Sep 17, 2019: Cassava Sciences to assess Alzheimer's drug in Phase IIb trial
    • Sep 17, 2019: Theranexus announces inclusion of last subject in its phase IB trial of THN201
    • Sep 16, 2019: Biogen and Eisai discontinue Alzheimer's trials of BACE inhibitor
    • Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome
    • Sep 10, 2019: Neurotrope Alzheimer's Phase II trial fails to meet endpoints
    • Sep 10, 2019: Cognition Therapeutics' Founder/CSO to Provide Update on Elayta Clinical Progress at ADDF Alzheimer's Drug Discovery Conference
    • Sep 09, 2019: Cassava Sciences reports positive phase 2a clinical results in Alzheimer's Patients
    • Sep 09, 2019: New preclinical research suggests Tetra Therapeutics BPN14770 protects against memory loss and neuronal atrophy in Alzheimers disease
    • Sep 09, 2019: Axon announces positive results from phase II ADAMANT trial for AADvac1 in Alzheimers Disease
    • Sep 04, 2019: Cognition Therapeutics to give webcast presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook